GALAPAGOS NV (GLPG.AS)
BE0003818359 - Common Stock
Taking everything into account, GLPG scores 3 out of 10 in our fundamental rating. GLPG was compared to 77 industry peers in the Biotechnology industry. The financial health of GLPG is average, but there are quite some concerns on its profitability. GLPG does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
GLPG had positive earnings in the past year.
GLPG had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: GLPG reported negative net income in multiple years.
GLPG had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 6.10%, GLPG belongs to the best of the industry, outperforming 93.06% of the companies in the same industry.
GLPG has a Return On Equity of 9.51%. This is amongst the best in the industry. GLPG outperforms 90.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.1% | ||
| ROE | 9.51% | ||
| ROIC | N/A |
ROA(3y)-0.58%
ROA(5y)-0.92%
ROE(3y)-1.65%
ROE(5y)-2.24%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GLPG's Profit Margin of 34.26% is amongst the best of the industry. GLPG outperforms 97.22% of its industry peers.
GLPG does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 34.26% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GLPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GLPG has about the same amount of shares outstanding.
The number of shares outstanding for GLPG has been increased compared to 5 years ago.
Compared to 1 year ago, GLPG has an improved debt to assets ratio.
2.2 Solvency
GLPG has an Altman-Z score of 1.67. This is a bad value and indicates that GLPG is not financially healthy and even has some risk of bankruptcy.
GLPG has a better Altman-Z score (1.67) than 63.89% of its industry peers.
GLPG has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, GLPG belongs to the top of the industry, outperforming 90.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.67 |
ROIC/WACCN/A
WACC7.64%
2.3 Liquidity
A Current Ratio of 9.02 indicates that GLPG has no problem at all paying its short term obligations.
GLPG has a Current ratio of 9.02. This is amongst the best in the industry. GLPG outperforms 91.67% of its industry peers.
A Quick Ratio of 8.84 indicates that GLPG has no problem at all paying its short term obligations.
The Quick ratio of GLPG (8.84) is better than 91.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.02 | ||
| Quick Ratio | 8.84 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 197.91% over the past year.
The Revenue has grown by 40.53% in the past year. This is a very strong growth!
GLPG shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.02% yearly.
EPS 1Y (TTM)197.91%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q175.63%
Revenue 1Y (TTM)40.53%
Revenue growth 3Y-18.51%
Revenue growth 5Y-2.02%
Revenue growth Q2Q155.12%
3.2 Future
GLPG is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -28.70% yearly.
The Revenue is expected to decrease by -2.19% on average over the next years.
EPS Next Y-147.18%
EPS Next 2Y-59.08%
EPS Next 3Y-37.01%
EPS Next 5Y-28.7%
Revenue Next Year-23.19%
Revenue Next 2Y-18.78%
Revenue Next 3Y-13.47%
Revenue Next 5Y-2.19%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 8.17, the valuation of GLPG can be described as reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of GLPG indicates a rather cheap valuation: GLPG is cheaper than 100.00% of the companies listed in the same industry.
GLPG is valuated cheaply when we compare the Price/Earnings ratio to 25.20, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for GLPG. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.17 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as GLPG's earnings are expected to decrease with -37.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-59.08%
EPS Next 3Y-37.01%
5. Dividend
5.1 Amount
No dividends for GLPG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GALAPAGOS NV
AMS:GLPG (4/25/2024, 7:00:00 PM)
26.56
-0.56 (-2.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.75B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.17 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.1% | ||
| ROE | 9.51% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | 34.26% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.02 | ||
| Quick Ratio | 8.84 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)197.91%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-147.18%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)40.53%
Revenue growth 3Y-18.51%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y